
Graham Collins, MBBS, on New Agents, Prognostic Models in Hodgkin Lymphoma
The HemOnc Pulse
00:00
Nivo ICE - Phase Two Single Arm Study?
I don't think Nivo ICE will get a license because it's only, well, I don't think anyone's applying for a license because the trial is so small. The EMA, and actually now since Brexit, we've even got our own licensing authority in the UK. It's the MHRA. And then of course, even if it were licensed in England, it has to go through NICE. So sadly, I'm not holding my breath actually for us to be able to use checkpoint combos. But that's still, we still need randomized studies in these areas. Hard to do, you know, but we can do them.
Transcript
Play full episode